Thioaptamers targeting dengue virus type-2 envelope protein domain III

Biochem Biophys Res Commun. 2014 Oct 24;453(3):309-15. doi: 10.1016/j.bbrc.2014.09.053. Epub 2014 Sep 26.


Thioaptamers targeting the dengue-2 virus (DENV-2) envelope protein domain III (EDIII) were developed. EDIII, which contains epitopes for binding neutralizing antibodies, is the putative host-receptor binding domain and is thus an attractive target for development of vaccines, anti-viral therapeutic and diagnostic agents. Thioaptamer DENTA-1 bound to DENV-2 EDIII adjacent to a known neutralizing antibody binding site with a dissociation constant of 154nM.

Keywords: Anti-viral; Dengue virus; Diagnostic agent; Envelope protein; SELEX; Thioaptamer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing / immunology
  • Antiviral Agents / pharmacology*
  • Aptamers, Nucleotide / chemistry
  • Aptamers, Nucleotide / pharmacology*
  • Base Sequence
  • Dengue Virus / chemistry
  • Dengue Virus / drug effects*
  • Magnetic Resonance Spectroscopy
  • Viral Envelope Proteins / chemistry
  • Viral Envelope Proteins / drug effects*
  • Viral Envelope Proteins / immunology


  • Antibodies, Neutralizing
  • Antiviral Agents
  • Aptamers, Nucleotide
  • Viral Envelope Proteins